SVR, 35% spleen volume reduction; TSS, 50% reduction in total symptom score.
1Physician’s Choice is limited to single drugs from the following list: corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib.
*Current or prior JAK2 inhibitor patients may be eligible if this treatment meets at least one of the following criteria:
Prior treatment with any JAK2 inhibitor, irrespective of dose, with a duration of 90 days or less.
Prior treatment with ruxolitinib, at no more than 10 mg total daily dose on any day, with a duration of 180 days or less.
© Copyright 2021 CTI BioPharma Corp.